The Food and Drug Administration granted priority review status to Clovis Oncology's experimental cancer drug.
Rucaparib, which earned the FDA's Breakthrough Therapy Designation in April 2015, is intended to treat patients with advanced ovarian cancer.
The agency's priority review process was created to decrease the time it takes to put promising new medicines on the market. The FDA expects to make a decision on the drugs approval by February 2017.
Upon news of the drug's priority review status, shares of Boulder, Colo.–based Clovis jumped almost 30 percent to $23.40.
More articles on the drug market:
Pfizer to buy AstraZeneca's antibiotics portfolio: 6 things to know
FDA: Drug companies abuse citizen petitions to block generic competition
EpiPen isn't the only drug with a price hike: Insulin prices skyrocket